Economists and legal scholars have debated the reasons people adopt opensource software, and accordingly whether and to what extent the open-source model can scale, replacing proprietary rights as a primary means of production. In this Article, we use the release by a biotechnology company of similar software under both proprietary and open-source licenses to investigate who uses open-source software and why. We find that academic users are somewhat more likely to adopt open-source software than private firms. We find only modest differences in the willingness of open-source users to modify or improve existing programs. And we find that users of open-source software often make business decisions that seem indifferent to the norms of opensource distribution. Our findings cast some doubt on the penetration of the open-source ethos beyond traditional software markets. t William H. Neukom Professor of Law, Stanford Law School; Partner, Durie Tangri LLP.
I. BACKGROUND
The traditional theory of intellectual property (IP) is well understood. Creators of intellectual content would have insufficient incentive to create if their works could be cheaply and quickly imitated. Thus, the law grants legal control over new creations in order to prevent, delay, or raise the cost of imitation and therefore encourage investment in creation.
The rise of open-source software poses an important challenge to the classic account of the production of intellectual public goods. Instead of using IP rights to optimize monetary benefit, open-source production relies on IP rights to keep software, and any improvements or additions to it, free and widely accessible. Open-source software is provided to others for free; providers profit, if at all, not by selling the software or improvements to it but by providing consulting or other services.
Scholars vigorously debate whether open-source software represents a fundamental new means of collaborative production potentially extendable to other forms of human endeavor 2 or an altruistic fringe to the dominant market-based model of production. For economists in particular, this debate is intimately bound up with questions about the motivations of those who participate in open-source production. If the classic theory of IP holds-if people are rational economic actors who will create only if the expected rewards exceed the costs-then open-source production is likely to be limited to the creation of relatively low-cost or small-scale products, primarily by those who do it in their spare time out of altruism or intellectual curiosity or who are otherwise subsidized (perhaps by a government or university) to create software without being paid for it. 4 By contrast, if people are collectively motivated to create by nonfinancial incentives, or if there is a sustainable market for the provision of services ancillary to opensource products,' the open-source model could conceivably displace proprietary software and even extend to products other than software, such as DNA databases. ' The economic literature has made substantial strides in trying to explain and characterize the free and open software movement. Explanations focus on social norms and ethics that reward contributors in nonmonetary ways (for example by enhancing reputation in a community),' on the unique characteristics of software as a network good and the corresponding possibility of monetizing services or ancillary products, 8 
II. OUR STUDY
In this study, we take advantage of a natural experiment in the provision of software in the bioinformatics industry to test motivations and usage patterns for open-source and proprietary software. Affymetrix, a company that sells microarrays (branded as "GeneChips") for use in DNA-based laboratory tests, provides software that enables purchasers to use the chips and analyze the results." Specifically, Affymetrix and other companies have developed several algorithms that summarize the chip probe-set results and normalize the resulting data, allowing users of the Affymetrix GeneChip to analyze and understand the results of the chip probes. They have in turn implemented these algorithms in a variety of software programs.
Importantly, Affymetrix makes available both open-source and proprietary versions of the same basic algorithms and software.1 2 Called "dual licensing" or "versioning," this dual release strategy is To test those usage patterns, we conducted two studies. First, we reviewed publications from Affymetrix's "Scientific Publications" page for the period from 2007 to 2008." In all, we found 178 publications that make reference to algorithms of software for interpreting data from the Affymetrix GeneChip. We collected data on the entity status of each author, and on the algorithm and the software those authors used. When users write papers disclosing results made using the GeneChip, they almost always cite the software they relied on to generate those results." As a result, we can learn about usage patterns by observing publication patterns.
Those usage patterns will be biased, however, because they represent not all users of Affymetrix GeneChips but only those who publish their results. That group is likely to include disproportionate numbers of academic and nonprofit users. And indeed we find in the next Part that most publishers are academics. To ensure that private firm users are represented, we oversampled commercial users in the publication search. Publication also cannot account for intensity of use, though there should be some relationship between the two: those who use the chip to make a publishable discovery are likely to be 13 See Stefano Comino and Fabio M. Manenti, Dual Licensing in Open Source Software Markets *3-4 (unpublished manuscript, Jan 2010), online at http://ssrn.com/abstract=985529 (visited Oct 19, 2010); Robert W. Gomulkiewicz, Entrepreneurial Open Source Software Hackers: MySQL and Its Dual Licensing, 9 Computer L Rev & Tech J 203, 208-11 (2004) .
14 The test is not perfect, because the algorithms and software implementing those algorithms are not identical. First, we note that the algorithms and the software are not necessarily independent variables. For example, MAS 5.0 does not run the RMA algorithm, and GeneSpring does not run the MAS algorithm. As a result, some users might have chosen their software based on the algorithms rather than the open-source or proprietary issues. Second, since we study Affymetrix microarrays, our study sample is naturally biased toward users who have a greater propensity to choose the Affymetrix GCOS or MAS 5.0 software than do people buying Illumina microarrays. Notwithstanding these limitations, the programs are used for the same purpose, written by the same people, and have significant similarities. 15 For a full discussion of how those sources were selected, see Appendix B. 16 This is confirmed by survey data: 95.4 percent of academic users, 90.9 percent of other nonprofit users, and 80 percent of private firms who wrote a paper using the results cited the software in that paper. Overall, 250 of 270 survey respondents who published papers, or 92.6 percent, cited the software by name in the paper. For the original survey question, see Appendix C, question 14. more intensive users than those who do not, all other things being equal. Still, this is a limitation of the publication data.
To explore the motivations of users and the uses they make of the software, we supplement the literature search with a survey of users of the Affymetrix GeneChip. We sent out surveys to a wide range of individuals who have used the Affymetrix software and received 437 complete and usable responses." Of the 437 respondents, 305 (or 69.8 percent) were academics, 52 (or 11.9 percent) were nonprofit entities, and 80 (or 18.3 percent) were at private firms. The results indicate a predominance of academic users, but not surprisingly include more private firms than did the publication search.
III. RESULTS

A. Publication Data
For each published article, we studied the nature of the authors (academic, nonprofit, commercial, or mixed); if commercial, the industry (biotechnology or pharmaceuticals) in which the authors worked; whether the authors were domestic or foreign; and whether they used commercial or open-source software. We excluded from consideration review articles or meta-analyses in which the authors were not themselves running the experiments in which the data were collected, as well as articles that did not specify the software used. The summary results are presented in Table 1 . * When there were joint papers, we included them in either the commercial or academic category, but not both. We made this assessment based on who the lead author was and which side had the greater number of authors. Of the joint papers, six were primarily by academic authors and two were primarily commercial. ** As with joint authors, we treated papers as primarily either US or foreign in authorship.
In Table 2 , we explore how different actors vary in their use of open-source and proprietary software. The publication data suggest that academic users are far more likely to use open-source software than commercial entities; only a very small percentage of commercial users made use of open-source software, and half of those did so in the course of academiccommercial collaborations.
One possible explanation for this result is that commercial users want to release products using or incorporating the GeneChip software and charge for those products, something open-source licenses would restrict." We investigate that possibility in the next Part. Relatedly, commercial users may be worried about the risk of legal entanglement that comes with open-source software even if they are not now planning to release a product that incorporates that software. Another possibility is that commercial users expect proprietary software to be superior, with additional features or better usability, and are more willing than academic users to pay for that additional functionality.
B. Survey Data
With the assistance of Affymetrix, we surveyed users of Affymetrix GeneChips. We asked survey respondents a variety of questions, including which algorithms and which software they used, whether they were aware of other software, why they chose the version they did, whether they provided bug reports or fixes, whether they modified or improved the software, whether they released those modifications and 18 Exactly what form this restriction takes is a complicated question. A few open-source licenses, such as the BSD license, do not prevent licensees from charging for products. The GPL and related licenses, strictly speaking, allow the licensee to charge for products made using the license, but they also require that the code be made available for free, which makes the collection of revenue more difficult.
if so to whom, and whether they published their results." We can sort these results on the answer to any previous question; in much of what follows, we distinguish between those who used open-source software and algorithms and those who used proprietary software and algorithms.
We begin by replicating the analysis from the publication survey, measuring academic, nonprofit, and commercial users and users of opensource or proprietary software. The results appear in Tables 3 and 4 . There was also a survey option of "Other," in which the vast majority of people listed other less well-known proprietary softwarethese answers were included in the "proprietary" category.
We also had many users who used both open-source and proprietary software and algorithms. As a general matter, we have included joint users in both the open-source and proprietary software categories, but at various points we have separated them into their own group. We note that in Table 5 .
Curiously, the data here show no similar distinction between academic and commercial users. Indeed, commercial users made up the same percentage of users of both open-source and proprietary software. And we were unable to reject the hypothesis that each type of user was equally likely to use open-source or proprietary software. 2 We do find modest differences in the stated reasons why people employed particular programs. Those who used proprietary software gave the following answers: There are some differences here that line up with expectationsusers of open-source software put more emphasis on cost (47.5 versus 35 percent) and on ability to modify the software (42.4 versus 29.6 percent), for instance. But the overall differences are surprisingly modest. Indeed, differences between respondents' answers to the cost and ability to modify questions are the only ones that are statistically significant at a 99 percent confidence level. ' We also find modest differences in the use people make of the different types of software. One reason the data appear so noisy may be that these measures include a significant number of users who employed both open-source and proprietary GeneChip software at different times. This is the most logical way to explain the result that 35 percent of users of proprietary software stated "lower cost" as a reason for choosing the software they did, for example.' As a result, we also report a restricted sample limited to those who used only open-source or only proprietary software. ' The results of the restricted sample are more consistent with our expectations. We report the descriptive statistics in Table 5 . We emphasize, however, that the restricted sample is smaller and that none of these differences is statistically significant. Both sets in the restricted sample emphasized compatibility as a strong factor in software choice, suggesting a fair degree of path dependence driving the results. Open-source software users were more likely to emphasize the lower cost (64.9 versus 21.4 percent) and freedom to modify their software (54.1 versus 16.9 percent) ; proprietary software users were more likely to point to an existing institutional license (32.5 versus 2.7 percent) and the convenience of the software (37.7 versus 18.9 percent). ' We also find modest differences in the use people make of the different types of software in our restricted sample. We report those differences in Table 6 . Users of open-source software were not appreciably more likely to send fixes or bug reports back to the software developers- This is a curious result. Under the general terms of open-source software licenses, those who modify or contribute new software that they sell or distribute must make their new or modified code available to others. There might be an argument that open-source rules do not require that the source code be publicly distributed at all but simply provided on request.6 But even so, we find that most open-source users who released improved software did so only to their own customers (67.9 percent in the unrestricted sample; 83.3 percent in the restricted sample), despite the presumed obligation to make the code available to anyone who wanted it. Those who did release the software improvements usually did so under their own brand names-78.6 percent for open-source users (100 percent in the restricted sample) and 72.4 percent for proprietary software users (61.5 percent in the restricted sample).
Interestingly, the rationale that drove Affymetrix to release parallel programs in both open-source and proprietary formats-the belief that customers would want proprietary software because they hoped to improve on it and sell the improvement-does not appear to be borne out in the data. Some users of both open-source and proprietary software modified the software and released their modifications to the public as products. Users of open-source software were slightly more likely to modify the program than users of proprietary software. They were marginally more likely to release that software to the public, and marginally more likely to brand that improved software with their own mark. Again, however, we note that these differences are modest and not statistically significant.
IV. IMPLICATIONS
What stand out in these results are not the differences between open-source and proprietary software users but the similarities. Users of the probe-set summarization and normalization software seem largely indifferent to whether the software they use is open-source or proprietary. They often use multiple programs and algorithms, some of which are open source and some of which are proprietary. That sort of mixing is a big worry for open-source lawyers; indeed, there are companies designed to audit software code to make sure there is no inappropriate mixing.' Mixing is relevant primarily for those who change or improve code, not for passive users. But we find that roughly a quarter of users, including many users of both open-source and proprietary software, do in fact improve the software and release their
26
The GPL 2 provides that "[y]ou must make sure that [recipients], too, receive or can get the source code." GNU, General Public License, Version 2 (cited in note 12). This could be satisfied by a distribution on request. And the BSD license does not impose that constraint. 
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[78:139 improvements to others.' Curiously, even these improvers seem largely indifferent to the open-source-proprietary line, to the extent that many of them appear to be ignoring the fundamental constraint of open-source software-that you release your improvements to everyone. In fact, it is not clear that they are even aware of the limits on behavior that open-source licenses impose. This is a small study in a single industry, one in which the users are not primarily computer programmers. Further research may reveal whether our conclusion is merely an artifact of our study universe, whether similar behavior exists in more traditional open-source software contexts, or whether the result is driven by the fact that users This in turn inclines us to a policy of legal neutrality with regard to open-source and proprietary software.' Open-source software is not "better" than proprietary software, nor the reverse. Users wantand should have-the freedom to choose the right software for their particular purposes. But legal scholars need to understand that those users are often less concerned with the niceties of software licenses than with using whatever tool seems best suited to the job at hand. William Gibson famously said that "the street finds its own uses for things."" The same, it seems, can be said of technology licenses. We analyzed scientific publications to identify the software used to conduct primary probe-set summarization on Affymetrix Expression Analysis GeneChips. Probe-set summarization refers to the step of calculating raw expression data from the scanned image of a microarray. A publication was said to have used a particular software package if it was clear that probe-set summarization was being performed by the software in question. All other data-analysis steps such as normalization were not considered in deciding which software was used.
The following information was captured for each of the publications:
* Using the random number generator from www.random.org, a random number from one through nine was produced, which would correspond to a publication in the group of nine, with one denoting the publication on top, and nine denoting the publication on the bottom. There were 3,622 total publications in 2007, on a total of 363 different pages displaying groups of nine publications for each page. first an article from each page was chosen, but by page 50, the selection switched to choosing articles only from odd-numbered pages.
In total, we analyzed 203 academic publications. Of these, 121 proved useable for analysis. The rest were left out of the analysis because they: * were not accessible; * did not explicitly specify the software they were using to get probe-set summarization data; * were review articles or were meta-analyses of others' data, rather than reports of primary use of GeneChips; or * were not using Affymetrix "Expression Analysis Arrays."
B. Commercial Publications
We also analyzed publications from commercial companies. For commercial publications, we obtained a list of all of the scientific publications that cited Affymetrix in 2007 and 2008 from Martha Manion, head librarian of Affymetrix. This list denotes which publications are from commercial entities. As a result, we collected all publications by commercial entities, ensuring that there was not a selection bias in choosing the commercial publications. In total, we analyzed 110 publications; of these, 55 proved usable for analysis. We analyzed only publications by authors solely from commercial companies; no academiccommercial combinations were analyzed in this particular round of analysis. The exclusion criteria used for academic publications also applied here.
A full list of publications studied is available from the authors upon request. APPENDIX C. LIST OF SURVEY QUESTIONS [78:139 1. Do you use software algorithms to summarize the probe set and/or normalize raw expression data from Affymetrix GeneChips? These are the steps in GeneChip analysis that turn raw intensity data (.CEL files) into expression signal values (e.g., .CHP files) that can be compared from microarray to microarray for further analysis.
Answer Options
Response Frequency Response Count Yes No 2. Are you the person within your organization who decided which algorithm and software to use to summarize and/or normalize raw expression data?
Response 
